The objective of the project, funded by CEPI, is to address one of the key bottlenecks in RNA vaccine production: the time required to measure and assure critical quality attributes (CQAs). Current approaches often rely on multiple sequential assays, with testing timelines extending over several days and adding complexity to time-sensitive manufacturing processes.

“Our work with CEPI will evaluate how NMR technology can be integrated directly into the manufacturing workflow to enable real-time, simultaneous monitoring of multiple CQAs. By shifting from traditional off-line testing to in-line analytical measurement, our new method has the potential to significantly accelerate quality assessment and batch release timelines, enabling faster manufacturing process,” says Aaron Cowley, Chief Scientific Officer at Analysis Zero.

Analysis Zero brings expertise in advanced analytical technologies and process integration, while Recipharm contributes its experience in biologics development and manufacturing. Together, the teams will explore how this innovative PAT approach can simplify quality control while maintaining the highest standards of product integrity.